Everything else on this site is about switching the GLP-1 receptor on. This drug switches it off, and for a condition caused by the receptor being switched on too hard.
What the condition is
After a gastric bypass, food reaches the small intestine faster than it used to, and the gut releases far more GLP-1 than it should. That drives an insulin surge an hour or two after eating, and blood sugar crashes. [1]
It complicates up to 30% of Roux-en-Y procedures and up to 10% of sleeve gastrectomies, and the same picture follows total gastrectomy, esophagectomy and Nissen fundoplication. People describe confusion, sweating and blackouts after ordinary meals.
Nobody with this is a candidate for a GLP-1 agonist. It is the mirror image of the regain that sends people back to these drugs after surgery — a different complication of the same operation, needing the opposite molecule.
What the study found
Sixteen people completed it, n = 16. Each spent fourteen days on 45 mg twice daily and fourteen on 90 mg once daily, in random order, after a fourteen-day baseline.
Daytime severe lows measured by continuous glucose monitoring fell 47.7% and 59.0%. Severe events adjudicated centrally fell 67.5% and 66.1%. Time below 54 mg/dL fell 45% and 64%. Quality-of-life scores improved on the once-daily dose. No serious adverse events, nobody stopped — and a crossover design like this one asks each person to serve as their own control, which is a strength on a measurement this dense and a weakness without a comparison arm.
Why sixteen is both small and not
For a common condition, sixteen people would be nothing. For this one it is a reasonable phase 2b, because the population is narrow and the outcome is measured continuously rather than counted as rare events.
A monitor reading glucose every few minutes for six weeks produces a great deal of data per person, which is why the intervals here behave better than 446 patients counting four deaths managed to.
What it means for this market
Nothing directly. Avexitide is investigational, sold nowhere, and treats a complication of surgery rather than anything a reader here is buying.
What it shows is that the receptor has two useful directions, which is a reminder that the appetite effect is not a free-standing benefit but one end of a system — the same system behind food still sitting in a stomach after twelve hours.
If you had bariatric surgery and get shaky or confused an hour after eating, that is worth raising with whoever operated. It has a name and it is treatable.